SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Sep 21, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Sept. 21, 2016 · CIK: 0001604191 · Accession: 0001415889-16-007171
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212511
Letter
Re: AzurRx BioPharma, Inc.
azrxcorrespco_sept142016.htm
September 21, 2016
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
AzurRx BioPharma, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on September 21, 2016, or as soon thereafter as practicable.
The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”), or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, such declaration does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under federal securities laws of the United States.
Very truly yours,
AZURRX BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
azrxcorrespco_sept142016.htm
September 21, 2016
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
Re: AzurRx BioPharma, Inc.
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
AzurRx BioPharma, Inc. (the “Company”) hereby requests that the effective date of the above-captioned Registration Statement be accelerated to 5:00 p.m. on September 21, 2016, or as soon thereafter as practicable.
The Company acknowledges that (i) should the Securities and Exchange Commission (the “Commission”), or the staff, acting pursuant to delegated authority, declare the Registration Statement effective, such declaration does not foreclose the Commission from taking any action with respect to the Registration Statement; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under federal securities laws of the United States.
Very truly yours,
AZURRX BIOPHARMA, INC.
By:
/s/ Johan M. (Thijs) Spoor
Name: Johan M. (Thijs) Spoor
Title: President and Chief Executive Officer